Cycling News

Canyon-SRAM rider Shari Bossuyt tests positive for Letrozole

Canyon-SRAM rider Shari Bossuyt tests positive for Letrozole

Shari Bossuyt from the Canyon-Sram team, has been suspended from racing testing positive for Letrozole, a prohibited substance. Letrozole is usually prescribed for the treatment of estrogen-sensitive cancer in post-menopausal women. Its potential doping effect is comparable to testosterone, which is why it is included on WADA’s list of banned substances. Bossuyt is the current madison world champion.

In 2022, ‘cross rider Toon Aerts also tested positive for Letrozole in late 2022. Despite denying any wrongdoing and refusing to accept a two-year suspension, Aerts has been unable to provide evidence supporting his claim that his case was a result of contamination.

Canyon/Sram posted a statement about the A and B sample positive on Sunday on Twitter.

“Canyon/SRAM Racing has a zero-tolerance stance towards any use of prohibited substances in accordance with WADA Anti-Doping Regulations. Adherence to the anti-doping rules is therefore part of all contracts between all riders and Canyon/SRAM Racing,” the statement read. “In accordance with its own anti-doping rules, the team has made Shari provisionally non-active for Canyon/SRAM Racing. The team is now waiting for the decision of The French Anti-Doping Agency before taking any further action.”

Bossuyt and her manager are scheduled to hold a press conference in Belgium on Monday. T

Click Here to Read the Full Original Article at Canadian Cycling Magazine…